Orphazyme CEO on trading explosion: "We have no idea what is going on"

The Danish company has not made any announcements over the past 24 hours, so CEO Christophe Bourdon is very surprised at the 300 percent value jump its shares made in the US on Thursday, which rubbed off on the Danish listing on Friday.

CEO Christophe Bourdon is as confused by the developments as anyone. | Photo: Orphazyme / PR

Thursday was a noteworthy day for Orphazyme in every sense of the word.

When trading closed on the Nasdaq exchange in Copenhagen on Thursday, the share price had dropped by 0.2 percent, giving the company a share value of DKK 31.1.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs